- Home
- CLLS vs STXS Comparison
CLLS vs STXS Comparison
Compare CLLS & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- STXS
- Stock Information
- Founded
- CLLS 1999
- STXS 1990
- Country
- CLLS France
- STXS United States
- Employees
- CLLS N/A
- STXS N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CLLS Health Care
- STXS Health Care
- Exchange
- CLLS Nasdaq
- STXS Nasdaq
- Market Cap
- CLLS 143.4M
- STXS 151.3M
- IPO Year
- CLLS 2007
- STXS 2004
- Fundamental
- Price
- CLLS $2.95
- STXS $2.22
- Analyst Decision
- CLLS Buy
- STXS
- Analyst Count
- CLLS 1
- STXS 0
- Target Price
- CLLS $4.00
- STXS N/A
- AVG Volume (30 Days)
- CLLS 310.2K
- STXS 651.2K
- Earning Date
- CLLS 08-04-2025
- STXS 08-07-2025
- Dividend Yield
- CLLS N/A
- STXS N/A
- EPS Growth
- CLLS N/A
- STXS N/A
- EPS
- CLLS N/A
- STXS N/A
- Revenue
- CLLS $54,747,000.00
- STXS $27,510,000.00
- Revenue This Year
- CLLS N/A
- STXS $29.03
- Revenue Next Year
- CLLS $4.90
- STXS $44.05
- P/E Ratio
- CLLS N/A
- STXS N/A
- Revenue Growth
- CLLS 351.26
- STXS 1.50
- 52 Week Low
- CLLS $1.10
- STXS $1.54
- 52 Week High
- CLLS $3.10
- STXS $2.72
- Technical
- Relative Strength Index (RSI)
- CLLS 69.22
- STXS 47.07
- Support Level
- CLLS $2.43
- STXS $2.20
- Resistance Level
- CLLS $3.10
- STXS $2.67
- Average True Range (ATR)
- CLLS 0.27
- STXS 0.16
- MACD
- CLLS 0.08
- STXS -0.01
- Stochastic Oscillator
- CLLS 88.72
- STXS 21.05
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About STXS Stereotaxis Inc.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.